In this trial, patients with PD-L1 positive, unresectable stage III NSCLC who did not progress on cCRT will be randomized to receive standard-of-care durvalumab with domvanalimab (anti-TIGIT) or a placebo [52]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.